Feline Adipose Stem Cell Reprogramming for Insulin-Secreting β Cells
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is no effective cure for feline diabetes, and existing insulin treatments are cumbersome and prone to complications due to species differences, requiring customized and time-consuming therapy.
Innovation Solution
Transdifferentiation of feline adipose-derived multipotent stromal cells (ASCs) into pancreatic β cells using a three-stage culture process involving specific growth factors and media compositions to produce functional insulin-secreting cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If exogenous insulin administration is used to treat feline diabetes, then glucose levels can be controlled, but the treatment is cumbersome and requires daily injections with customized therapy for each patient
Solution Approach 1:
The patent creates autologous pancreatic β cells from the cat's own adipose-derived stem cells, enabling the animal's body to produce its own insulin endogenously. This eliminates the need for daily exogenous insulin injections and customized therapy regimens, as the regenerated β cells will automatically sense glucose levels and secrete appropriate amounts of insulin without human intervention.
Solution Approach 2:
The patent performs preliminary expansion and differentiation of adipose-derived stem cells in vitro before implantation, creating a population of insulin-producing cells in advance. This preliminary action allows the regenerative therapy to be prepared once and then provide sustained glucose control without requiring ongoing customized adjustments or daily administration.
2Reliability
If available insulin formulations are used, then biological activity is maintained across species, but sequence differences may affect activity and stimulate the immune system
Solution Approach 1:
By regenerating endogenous feline pancreatic β cells from the cat's own adipose-derived stem cells, the patent ensures that the insulin produced is authentic feline insulin with the correct amino acid sequence. This eliminates immune system stimulation that would occur with xenogeneic insulin formulations, as the immune system recognizes the endogenously produced insulin as self and does not mount an immune response.
Solution Approach 2:
The patent changes the source of insulin from exogenous formulations (with potentially different amino acid sequences) to endogenously produced insulin from regenerated feline β cells. This parameter change ensures the insulin has the exact feline amino acid sequence, maintaining optimal biological activity while avoiding immune system stimulation from sequence differences.
3Quantity of substance
If adipose tissue is used as a source of starting cells, then cells can be obtained from routine sterilization procedures, but transdifferentiation efficiency must be optimized through specific culture conditions
Solution Approach 1:
The patent segments the transdifferentiation process into three distinct stages with specific culture conditions for each: Stage 1 (days 1-4) uses activin A and sodium butyrate to induce endodermal commitment; Stage 2 (days 5-9) uses specific growth factors to guide pancreatic differentiation; Stage 3 (days 10-14) optimizes β cell maturation and insulin production. This segmentation makes the complex transdifferentiation process more manageable and reproducible while utilizing readily available adipose tissue.
Solution Approach 2:
The patent optimizes transdifferentiation efficiency by systematically changing culture parameters at each stage: adjusting growth factor concentrations, changing medium compositions, and modifying culture conditions to match the specific requirements of each differentiation stage. These parameter changes enable efficient conversion of adipose-derived stem cells to functional β cells while starting from easily obtained tissue from routine sterilization procedures.
Data Source
AI summary
Compositions and methods are described herein for transdifferentiation of multipotent stromal cells into cells that can express insulin.